Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.